Page last updated: 2024-11-05

ticlopidine and Hyperlipoproteinemia Type II

ticlopidine has been researched along with Hyperlipoproteinemia Type II in 2 studies

Ticlopidine: An effective inhibitor of platelet aggregation commonly used in the placement of STENTS in CORONARY ARTERIES.
ticlopidine : A thienopyridine that is 4,5,6,7-tetrahydrothieno[3,2-c]pyridine in which the hydrogen attached to the nitrogen is replaced by an o-chlorobenzyl group.

Hyperlipoproteinemia Type II: A group of familial disorders characterized by elevated circulating cholesterol contained in either LOW-DENSITY LIPOPROTEINS alone or also in VERY-LOW-DENSITY LIPOPROTEINS (pre-beta lipoproteins).

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19901 (50.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Yamamoto, H1
Takada, T1
Yamanashi, Y1
Ogura, M1
Masuo, Y1
Harada-Shiba, M1
Suzuki, H1
Di Minno, G1
Cerbone, AM1
Iride, C1
Mattioli, PL1
Postiglione, A1
Mancini, M1

Other Studies

2 other studies available for ticlopidine and Hyperlipoproteinemia Type II

ArticleYear
VLDL/LDL acts as a drug carrier and regulates the transport and metabolism of drugs in the body.
    Scientific reports, 2017, 04-04, Volume: 7, Issue:1

    Topics: Amlodipine; Animals; Biological Transport; Cholesterol; Drug Carriers; Hyperlipoproteinemia Type II;

2017
Platelet fibrinogen binding in familial hypercholesterolemia.
    Advances in experimental medicine and biology, 1987, Volume: 210

    Topics: Adenosine Diphosphate; Adolescent; Adult; Blood Platelets; Child; Female; Fibrinogen; Humans; Hyperl

1987